Karamched, Saketh R.
Nosoudi, Nasim
Moreland, Hannah E.
Chowdhury, Aniqa
Vyavahare, Naren R.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (P20GM103444, R01HL133662)
Article History
Received: 22 August 2018
Accepted: 23 January 2019
First Online: 22 February 2019
Competing Interests
: NRV holds significant equity in Elastrin Therapeutics Inc., which has licensed this technology from Clemson University.